Pulse Biosciences COO Liane Teplitsky buys $99,971 in company stock

Liane Teplitsky, Chief Operating Officer of Pulse Biosciences (NASDAQ:PLSE), purchased company shares totaling $99,971 through open-market transactions on August 31 and September 1, 2026, acquiring 2,025 shares at prices between $48.80 and $49.95 per share. The purchases occurred during an open trading window and in compliance with securities laws. Following the transactions, Teplitsky holds 4,095 shares valued at approximately $216,000. The stock trades near $52.68, close to its 52-week high, after a 284% year-to-date gain, though InvestingPro analysis suggests the shares appear overvalued. Pulse Biosciences recently reported a larger-than-expected second-quarter loss of $0.36 per share, missing estimates, with revenue of $400,000 below forecasts. Despite this, Canaccord raised its price target to $43, and Needham initiated coverage with a $58 target, citing progress in the company's nanosecond pulsed field ablation platform.